The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,339K data for 617K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

58 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.EBI
Bristol-Myers Squibb
Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI
Bristol-Myers Squibb
Pyridine and pyridinone-based factor XIa inhibitors.EBI
Bristol-Myers Squibb
Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.EBI
TBA
Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.EBI
Bristol-Myers Squibb
Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI
Bristol-Myers Squibb
Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.EBI
Bristol-Myers Squibb
Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.EBI
Bristol-Myers Squibb
Inhibitors of Factor XIa and Plasma Kallikrein May Treat Thromboembolic Disorders and Many Diabetes Complications.EBI
Therachem Research Medilab (India)
Inactivation of trypsin-like proteases by sulfonylation. Variation of positively charged group and inhibitor length.EBI
TBA
Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.EBI
Hiroshima International University
Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy.EBI
Ecole Polytechnique F�D�Rale De Lausanne Epfl
Development of new cyclic plasmin inhibitors with excellent potency and selectivity.EBI
Philipps University Marburg
Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.EBI
Celera Genomics
A new strategy for the development of highly potent and selective plasmin inhibitors.EBI
Philipps University Marburg
Human kallikrein 6 inhibitors with a para-amidobenzylanmine P1 group identified through virtual screening.EBI
Sanofi Pharmaceuticals
Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation.EBI
University Of Florida
Inhibitors of proteases and amide hydrolases that employ an alpha-ketoheterocycle as a key enabling functionality.EBI
Johnson & Johnson Pharmaceutical Research & Development
Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.EBI
Bristol-Myers Squibb Research And Development
SAR and X-ray structures of enantiopure 1,2-cis-(1R,2S)-cyclopentyldiamine and cyclohexyldiamine derivatives as inhibitors of coagulation Factor Xa.EBI
Bristol-Myers Squibb
Selective inhibitors of the serine protease plasmin: probing the S3 and S3' subsites using a combinatorial library.EBI
Brown University
Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).EBI
Pharmaceutical Research Institute
Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.EBI
Dupont Pharmaceuticals
Protease inhibitors: current status and future prospects.EBI
University Of Queensland
Synthesis of a series of potent and orally bioavailable thrombin inhibitors that utilize 3,3-disubstituted propionic acid derivatives in the P3 position.EBI
Merck Research Laboratories
Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.EBI
Klinikum Der Friedrich-Schiller-Universit£T Jena
Inhibition studies of some serine and thiol proteinases by new leupeptin analogues.EBI
University Of Arkansas
Synthesis of potent and selective inhibitors of human plasma kallikrein.EBI
The Procter & Gamble
 
L-373,890, An achiral, noncovalent, subnanomolar thrombin inhibitorEBI
TBA
The arginine mimickingß-amino acidß³hPhe(3-H2N-CH2) as S1 ligand in cyclotheonamide-basedß-tryptase inhibitors.EBI
Universit£T Bielefeld
Discovery of N-[2-hydroxy-6-(4-methoxybenzamido)phenyl]-4- (4-methyl-1,4-diazepan-1-yl)benzamide (darexaban, YM150) as a potent and orally available factor Xa inhibitor.EBI
Astellas Pharma
Identification of novel plasmin inhibitors possessing nitrile moiety as warhead.EBI
Hiroshima International University
Development of substrate analogue inhibitors for the human airway trypsin-like protease HAT.EBI
Philipps University Marburg
Phage-encoded combinatorial chemical libraries based on bicyclic peptides.EBI
Laboratory Of Molecular Biology, Medical Research Council
 
Characterization of LY806303 as a potent and selective inhibitor of thrombinEBI
TBA
Enantiopure five-membered cyclicdiamine derivatives as potent and selective inhibitors of factor Xa. Improving in vitro metabolic stability via core modifications.EBI
Bristol-Myers Squibb
Selective and dual action orally active inhibitors of thrombin and factor Xa.EBI
Glaxosmithkline
Novel, potent, selective, and orally bioavailable human betaII-tryptase inhibitors.EBI
Celera Genomics
Small molecule inhibitors of plasma kallikrein.EBI
Celera Genomics
Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.EBI
Bristol-Myers Squibb Pharmaceutical Research Institute
Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity.EBI
Millennium Pharmaceuticals
Identification of novel binding interactions in the development of potent, selective 2-naphthamidine inhibitors of urokinase. Synthesis, structural analysis, and SAR of N-phenyl amide 6-substitution.EBI
Abbott Laboratories
3-Amidinophenylalanine-based inhibitors of urokinase.EBI
UniversitäT Jena
Design of benzamidine-type inhibitors of factor Xa.EBI
Institut FüR Biochemie
Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position.EBI
Merck Research Laboratories
Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.EBI
Merck Research Laboratories
 
Novel multi-targeted agents for Alzheimer's disease: Synthesis, biological evaluation, and molecular modeling of novel 2-[4-(4-substitutedpiperazin-1-yl)phenyl]benzimidazolesBDB
Hacettepe University
Design, synthesis, and biological evaluation of hydroquinone derivatives as novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase.BDB
Northern Kentucky University